ArticlePLoS medicine2019
Homogeneity in the association of body mass index with type 2 diabetes across the UK Biobank: A Mendelian randomization study.
Article in PLoS medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Effect of exercise alone and in combination with time-restricted eating on cardiometabolic health in menopausal women.Journal of translational medicine · 2024Trial
- Advances in Metabolomics: A Comprehensive Review of Type 2 Diabetes and Cardiovascular Disease Interactions.International journal of molecular sciences · 2025Review
- Metformin Increased Histone Deacetylases 1, 3, and 8 Expressions as Epigenetic Regulators in Type 2 Diabetic Patients.Reports of biochemistry & molecular biology · 2025Article
- Dietary patterns and obesity are associated with type 2 diabetes risk in elderly Chinese men: a machine learning approach.Frontiers in nutrition · 2025Article
- Genetics-driven risk predictions leveraging the Mendelian randomization framework.Genome research · 2024Article
- DeepRisk: A deep learning approach for genome-wide assessment of common disease risk.Fundamental research · 2024Article
- Body mass index stratification optimizes polygenic prediction of type 2 diabetes in cross-biobank analyses.Nature genetics · 2024Article
- Review
- Systematic comparison of Mendelian randomisation studies and randomised controlled trials using electronic databases.BMJ open · 2023Article
- Causal factors underlying diabetes risk informed by Mendelian randomisation analysis: evidence, opportunities and challenges.Diabetologia · 2023Review
- Adipose tissue specific CCL18 associates with cardiometabolic diseases in non-obese individuals implicating CD4Cardiovascular diabetology · 2023Article
- Association of cardiovascular health metrics with annual incidence of prediabetes or diabetes: Analysis of a nationwide real-world database.Journal of diabetes investigation · 2023Article
- Epidemiology of neuropathic pain: an analysis of prevalence and associated factors in UK Biobank.Pain reports · 2023Article
- Birthweight, BMI in adulthood and latent autoimmune diabetes in adults: a Mendelian randomisation study.Diabetologia · 2022Article
- New Horizons: the value of UK Biobank to research on endocrine and metabolic disorders.The Journal of clinical endocrinology and metabolism · 2022Article
- Network Mendelian randomization study: exploring the causal pathway from insomnia to type 2 diabetes.BMJ open diabetes research & care · 2022Article
- Composite trait Mendelian randomization reveals distinct metabolic and lifestyle consequences of differences in body shape.Communications biology · 2021Article
- The Need for a Human Pangenome Reference Sequence.Annual review of genomics and human genetics · 2021Review
- Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development.Nature reviews. Cardiology · 2021Review
- Genetics of 35 blood and urine biomarkers in the UK Biobank.Nature genetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundLifestyle interventions to reduce body mass index (BMI) are critical public health strategies for type 2 diabetes prevention. While weight loss interventions have shown demonstrable benefit for high-risk and prediabetic individuals, we aimed to determine whether the same benefits apply to those at lower risk. METHODS AND
findingsWe performed a multi-stratum Mendelian randomization study of the effect size of BMI on diabetes odds in 287,394 unrelated individuals of self-reported white British ancestry in the UK Biobank, who were recruited from across the United Kingdom from 2006 to 2010 when they were between the ages of 40 and 69 years. Individuals were stratified on the following diabetes risk factors: BMI, diabetes family history, and genome-wide diabetes polygenic risk score. The main outcome measure was the odds ratio of diabetes per 1-kg/m2 BMI reduction, in the full cohort and in each stratum. Diabetes prevalence increased sharply with BMI, family history of diabetes, and genetic risk. Conversely, predicted risk reduction from weight loss was strikingly similar across BMI and genetic risk categories. Weight loss was predicted to substantially reduce diabetes odds even among lower-risk individuals: for instance, a 1-kg/m2 BMI reduction was associated with a 1.37-fold reduction (95% CI 1.12-1.68) in diabetes odds among non-overweight individuals (BMI < 25 kg/m2) without a family history of diabetes, similar to that in obese individuals (BMI ≥ 30 kg/m2) with a family history (1.21-fold reduction, 95% CI 1.13-1.29). A key limitation of this analysis is that the BMI-altering DNA sequence polymorphisms it studies represent cumulative predisposition over an individual's entire lifetime, and may consequently incorrectly estimate the risk modification potential of weight loss interventions later in life.
conclusionsIn a population-scale cohort, lower BMI was consistently associated with reduced diabetes risk across BMI, family history, and genetic risk categories, suggesting all individuals can substantially reduce their diabetes risk through weight loss. Our results support the broad deployment of weight loss interventions to individuals at all levels of diabetes risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.